This segment focuses on the research, development, and commercialization of treatments for rare and orphan diseases. Cerecor is actively developing monosaccharide therapies for congenital disorders of glycosylation (CDG), such as CERC-801, CERC-802, and CERC-803. Research and development activities include preclinical studies, clinical trials, and regulatory submissions. The company utilizes advanced technologies and methodologies in drug discovery and development, including the use of monoclonal antibodies and small molecules. The patient impact is significant, as these therapies address unmet medical needs in rare disease populations. Cerecor aims to establish a strong market position by focusing on innovative therapies and strategic partnerships, such as the collaboration with The Frontiers in Congenital Disorders of Glycosylation Consortium. Future opportunities include expanding the pipeline with additional rare disease candidates and securing regulatory approvals. Clinical trials are a key aspect of this segment, with a focus on demonstrating safety and efficacy in target patient populations.

This segment concentrates on developing therapies for immunological and inflammatory conditions. Cerecor is developing CERC-007, an anti-IL-18 monoclonal antibody, for the treatment of adult-onset Still's disease, multiple myeloma, and systemic juvenile idiopathic arthritis. Additionally, the company is involved in the development of CERC-002, an anti-LIGHT monoclonal antibody, which is in a phase 2 clinical trial for the treatment of COVID-19 acute respiratory distress syndrome and pediatric-onset Crohn's disease. Research and development activities include preclinical studies, clinical trials, and regulatory submissions. The company utilizes advanced technologies and methodologies in drug discovery and development, including the use of monoclonal antibodies. The patient impact is significant, as these therapies address unmet medical needs in patients suffering from autoimmune and inflammatory diseases. Cerecor aims to establish a strong market position by focusing on innovative therapies and strategic partnerships. Future opportunities include expanding the pipeline with additional candidates and securing regulatory approvals. Clinical trials are a key aspect of this segment, with a focus on demonstrating safety and efficacy in target patient populations.

This segment focuses on the commercialization of existing products, such as Millipred, an oral prednisolone for the treatment of inflammatory conditions. This includes sales, marketing, and distribution activities. The company leverages its existing infrastructure and partnerships to ensure market access and patient reach. The therapeutic areas covered include arthritis, blood disorders, immune system disorders, skin and eye conditions, respiratory disorders, cancer, and severe allergies. The patient impact is significant, as these products provide relief and improve the quality of life for patients with various inflammatory conditions. Cerecor aims to maintain a strong market position by providing high-quality products and excellent customer service. Future opportunities include expanding the product portfolio and exploring new markets. Regulatory compliance and quality assurance are critical aspects of this segment, ensuring that products meet the highest standards of safety and efficacy.